Innovotech Inc (IOT) Fair Value & Analysis
Technology · CA · Market cap €427M
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from €0.9200 to €1.04 (+13.0%) since Jun 23, 2026. Share price +18.8% over the past month.
Price vs Fair Value (12 months)
12‑month range €2.21 – €3.37 · fair‑value band €0.5100 – €1.81 · the €3.07 price screens above the €1.04 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Innovotech Inc (IOT) currently trades at €3.07, while our model-based Fair Value estimate is €1.04 — implying the stock looks roughly 66.1% overvalued today. We read business quality at 88/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Innovotech Inc generated revenue of €200M at a net margin of -0.4%. Revenue grew 3.0% year over year. It earns a return on equity of 0.8%. Net debt stands at €40.9M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the sector of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agr…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Innovotech Inc reported revenue of €198M in FY2025 versus €114M in FY2021, a compound +14.8%/yr. Reported net income was −€2.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Computer Hardware stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Compal Electronics, Inc CEIR | $3.10 | $6.35 | +105% |
| Dell Technologies Inc DELL | $422.05 | $454.86 | +8% |
| Arista Networks, Inc ANET | $174.56 | $79.13 | -55% |
| Western Digital Corporation WDC | $732.62 | $74.05 | -90% |
| Quanta Computer Inc 2382 | 370.00 TWD | 341.97 TWD | -8% |
| Hangzhou Hikvision Digital Technology Co 002415 | ¥31.28 | ¥23.47 | -25% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Innovotech Inc (IOT) undervalued?
What is the fair value of IOT?
What is the quality score of IOT?
What is the revenue of Innovotech Inc (IOT)?
What is the net profit margin of IOT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.